



G Medical Innovations Holdings Ltd  
ARBN 617 204 743

## ASX Announcement

25 May 2020

### Appendix 3Y

As disclosed in the attached Appendix 3Y, Yacov Geva the Managing Director of G Medical Innovations Holdings Limited (“GMV or “the Company”) has sold 47,125,000 GMV shares. The majority of the shares were sold to an institutional investor to repay a third-party loan which Mr Geva had secured in order to advance funds to the Company.

Mr Geva continues to hold 244,166,616 shares in the Company.

**Ends**

*Authorised for release by Yacov Geva, Managing Director.*

#### **About G Medical Innovations**

G Medical (**ASX: GMV**) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and e-health solutions using its suite of proprietary devices and software solutions, as well as patient service operations, with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

For more information on G Medical, please visit [www.gmedinnovations.com](http://www.gmedinnovations.com)

#### **About G Medical products:**

G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals.

The ‘Prizma’ Medical Smartphone Case is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The ‘Prizma’ allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members.

G Medical also offers a professional real-time patient continuous monitoring solution, G Medical’s Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge home-based settings.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b> G Medical Innovations Holdings Limited
<b>ARBN</b> 617 204 743

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Yacov Geva
<b>Date of last notice</b>	11 May 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	<ol style="list-style-type: none"> <li>1 Indirect</li> <li>2 Indirect</li> <li>3 Indirect</li> <li>4 Indirect</li> <li>5 Indirect</li> <li>6 Direct</li> </ol>
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<ol style="list-style-type: none"> <li>1 Beneficial holding held through and registered in the name of Bank Julius Baer &amp; Co Ltd</li> <li>2 Beneficial holding held through custodian and registered in the name of HSBC Custody Nominees (Australia) Limited</li> <li>3 Beneficial holding held through custodian and registered in the name of J P Morgan Nominees Australia Pty Limited</li> <li>4 Beneficial holding held through custodian and registered in the name of Millinium Capital Managers Limited</li> <li>5 Beneficial holding through custodian, Banque J Safra Sarasin</li> </ol>
<b>Date of change</b>	22 May 2020

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	<ol style="list-style-type: none"> <li>1 Nil</li> <li>2 3,672,000 fully paid ordinary shares</li> <li>3 181,978,322 fully paid ordinary shares</li> <li>4 4,990,000 fully paid ordinary shares</li> <li>5 89,700,294 fully paid ordinary shares</li> <li>6 10,951,000 fully paid ordinary shares</li> </ol>
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	Nil
<b>Number disposed</b>	<ol style="list-style-type: none"> <li>1. Nil</li> <li>2. Nil</li> <li>3. 47,125,000 fully paid ordinary shares</li> <li>4. Nil</li> <li>5. Nil</li> <li>6. Nil</li> </ol>
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	<ol style="list-style-type: none"> <li>a) \$0.07 per share for proceeds of \$3,080,000</li> <li>b) \$0.08 per share for proceeds of \$250,000</li> </ol>
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1 Nil</li> <li>2 3,672,000 fully paid ordinary shares</li> <li>3 137,978,322 fully paid ordinary shares</li> <li>4 4,990,000 fully paid ordinary shares</li> <li>5 86,575,294 fully paid ordinary shares</li> <li>6 10,951,000 fully paid ordinary shares</li> </ol>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<ol style="list-style-type: none"> <li>a) On-market trade by special crossing to an institutional investor</li> <li>b) Off market trade to an investor</li> </ol>

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.